Media headlines about Atara Biotherapeutics (NASDAQ:ATRA) have trended somewhat positive on Friday, according to Accern. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Atara Biotherapeutics earned a news impact score of 0.12 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.1527325401105 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:
- Atara Biotherapeutics Inc (ATRA) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)
- Atara Biotherapeutics Joins Elite Club Of Stocks With RS Ratings Over 90 (finance.yahoo.com)
- Atara Biotherapeutics Announces FDA Clearance to Proceed with Enrollment at U.S. Sites for Ongoing Global Phase 1 Clinical Study to Evaluate ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis (finance.yahoo.com)
- Investors Buy High Volume of Put Options on Atara Biotherapeutics (ATRA) (americanbankingnews.com)
- Atara Biotherapeutics Sees Unusually Large Options Volume (ATRA) (americanbankingnews.com)
Several equities research analysts have recently weighed in on ATRA shares. BidaskClub raised Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Thursday. Canaccord Genuity reissued a “buy” rating on shares of Atara Biotherapeutics in a research report on Friday, December 29th. Jefferies Group reissued a “buy” rating and issued a $30.00 price objective on shares of Atara Biotherapeutics in a research report on Thursday, October 5th. ValuEngine raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Finally, Citigroup upgraded Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 target price for the company in a research note on Wednesday, January 3rd. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $26.00.
Shares of Atara Biotherapeutics (ATRA) traded up $6.10 during midday trading on Friday, hitting $28.25. The company had a trading volume of 3,693,136 shares, compared to its average volume of 1,425,682. The firm has a market capitalization of $864.33, a price-to-earnings ratio of -8.14 and a beta of 1.27. Atara Biotherapeutics has a twelve month low of $11.80 and a twelve month high of $30.40.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.05). sell-side analysts forecast that Atara Biotherapeutics will post -4 EPS for the current fiscal year.
In other Atara Biotherapeutics news, EVP Christopher Haqq sold 6,000 shares of the stock in a transaction on Monday, October 16th. The stock was sold at an average price of $14.35, for a total transaction of $86,100.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Isaac E. Ciechanover sold 4,400 shares of the stock in a transaction on Friday, October 27th. The stock was sold at an average price of $13.59, for a total value of $59,796.00. Following the transaction, the chief executive officer now owns 737,767 shares of the company’s stock, valued at $10,026,253.53. The disclosure for this sale can be found here. Insiders have sold 121,788 shares of company stock valued at $2,194,934 over the last quarter. Corporate insiders own 16.20% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Atara Biotherapeutics (ATRA) Given Daily Media Impact Score of 0.12” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://ledgergazette.com/2018/01/12/atara-biotherapeutics-atra-getting-somewhat-favorable-press-coverage-analysis-shows.html.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.